Haluk Damgacioglu, Kalyani Sonawane, Gary M Clifford, Joel M Palefsky, Gweneth B Lazenby, Brian C Orr, Jane R Montealegre, Elizabeth Y Chiao, Keith M Sigel, Ashish A Deshmukh
{"title":"有外阴癌病史的女性肛门癌发病率的组织学、年龄和诊断后的时间。","authors":"Haluk Damgacioglu, Kalyani Sonawane, Gary M Clifford, Joel M Palefsky, Gweneth B Lazenby, Brian C Orr, Jane R Montealegre, Elizabeth Y Chiao, Keith M Sigel, Ashish A Deshmukh","doi":"10.1093/oncolo/oyaf307","DOIUrl":null,"url":null,"abstract":"<p><p>Women with a history of vulvar cancer face a high risk of anal cancer; however, incidence according to histology, age-at, and time since vulvar cancer diagnosis remains unexplored. Using data from SEER-8 and SEER-17 registries, we identified 21,230 women with vulvar cancer, with 154,825 person-years follow-up from 1975 to 2021. We observed 95 anal cancer cases, resulting in an incidence of 61.4 per 100,000 person-years (95% CI, 49.6-75.0). Incidence was higher among women with vulvar squamous cell carcinoma (SCC) (78.7; 95% CI, 62.9-97.1) than vulvar non-SCC (19.8; 95% CI, 9.0-37.6). The highest incidence (>100 per 100,000) was observed in women <45 years old with vulvar SCC and those >10 years post-diagnosis. These findings could inform anal cancer screening guidelines, as women with vulvar cancer, particularly those diagnosed with SCC, may substantially benefit from heightened surveillance or targeted screening.</p>","PeriodicalId":54686,"journal":{"name":"Oncologist","volume":" ","pages":""},"PeriodicalIF":4.2000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12517331/pdf/","citationCount":"0","resultStr":"{\"title\":\"Anal cancer incidence among women with a history of vulvar cancer by histology, age, and time since diagnosis.\",\"authors\":\"Haluk Damgacioglu, Kalyani Sonawane, Gary M Clifford, Joel M Palefsky, Gweneth B Lazenby, Brian C Orr, Jane R Montealegre, Elizabeth Y Chiao, Keith M Sigel, Ashish A Deshmukh\",\"doi\":\"10.1093/oncolo/oyaf307\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Women with a history of vulvar cancer face a high risk of anal cancer; however, incidence according to histology, age-at, and time since vulvar cancer diagnosis remains unexplored. Using data from SEER-8 and SEER-17 registries, we identified 21,230 women with vulvar cancer, with 154,825 person-years follow-up from 1975 to 2021. We observed 95 anal cancer cases, resulting in an incidence of 61.4 per 100,000 person-years (95% CI, 49.6-75.0). Incidence was higher among women with vulvar squamous cell carcinoma (SCC) (78.7; 95% CI, 62.9-97.1) than vulvar non-SCC (19.8; 95% CI, 9.0-37.6). The highest incidence (>100 per 100,000) was observed in women <45 years old with vulvar SCC and those >10 years post-diagnosis. These findings could inform anal cancer screening guidelines, as women with vulvar cancer, particularly those diagnosed with SCC, may substantially benefit from heightened surveillance or targeted screening.</p>\",\"PeriodicalId\":54686,\"journal\":{\"name\":\"Oncologist\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.2000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12517331/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncologist\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1093/oncolo/oyaf307\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncologist","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/oncolo/oyaf307","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
有外阴癌病史的女性患肛门癌的风险较高;然而,根据组织学,年龄和时间,外阴癌诊断的发病率仍未查明。使用SEER-8和SEER-17登记处的数据,我们确定了21,230名患有外阴癌的女性,从1975年到2021年进行了154,825人年的随访。我们观察到95例肛门癌病例,发生率为61.4 / 100000人-年(95% CI = 49.6 - 75.0)。外阴鳞状细胞癌(SCC)女性的发病率(78.7;95% CI = 62.9 ~ 97.1)高于非外阴鳞状细胞癌(19.8);95% CI = 9.0 ~ 37.6)。在诊断后10年的妇女中观察到最高的发病率(每10万人中有100人)。这些发现可以为肛门癌筛查指南提供信息,因为患有外阴癌的女性,特别是那些被诊断为SCC的女性,可能会从加强监测或有针对性的筛查中受益匪浅。
Anal cancer incidence among women with a history of vulvar cancer by histology, age, and time since diagnosis.
Women with a history of vulvar cancer face a high risk of anal cancer; however, incidence according to histology, age-at, and time since vulvar cancer diagnosis remains unexplored. Using data from SEER-8 and SEER-17 registries, we identified 21,230 women with vulvar cancer, with 154,825 person-years follow-up from 1975 to 2021. We observed 95 anal cancer cases, resulting in an incidence of 61.4 per 100,000 person-years (95% CI, 49.6-75.0). Incidence was higher among women with vulvar squamous cell carcinoma (SCC) (78.7; 95% CI, 62.9-97.1) than vulvar non-SCC (19.8; 95% CI, 9.0-37.6). The highest incidence (>100 per 100,000) was observed in women <45 years old with vulvar SCC and those >10 years post-diagnosis. These findings could inform anal cancer screening guidelines, as women with vulvar cancer, particularly those diagnosed with SCC, may substantially benefit from heightened surveillance or targeted screening.
期刊介绍:
The Oncologist® is dedicated to translating the latest research developments into the best multidimensional care for cancer patients. Thus, The Oncologist is committed to helping physicians excel in this ever-expanding environment through the publication of timely reviews, original studies, and commentaries on important developments. We believe that the practice of oncology requires both an understanding of a range of disciplines encompassing basic science related to cancer, translational research, and clinical practice, but also the socioeconomic and psychosocial factors that determine access to care and quality of life and function following cancer treatment.